VIR

Vir Biotechnology, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000

$11.30Close $1.6BMarket cap $5.12 – $11.9352-week range Nov 4, 2026Next report · after the close

Highlights

Strengths

In a stage-2 uptrend all 8 trend conditions pass
Leading the market RS 91 · stronger than 91% of stocks over 12 months
Volume drying up last 10 days 30% under the 50-day average

Cautions

Results soon Nov 4, 2026, in 3 days
Financial distress Altman Z″ in the distress zone

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 5, 2026

Off 12-month high 5%

1wk 6.9% price change

1mo 1.1% price change

12-month return 91% market up 11% · its own up 80%

F-score 4 / 9 Weak

Altman Z 1.30 Elevated risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 2.1× price / book

Earnings yield 35.7% EBIT / enterprise value

Cheaper than 25% of the market · expensive

Revenue growth 8% year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 46% return on equity

Free cash margin 579% -$396.6M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Piotroski tests

not yet profitable on its assets
operating cash flow is negative
profitability slipped from last year
short-term liquidity weakened
issued more shares
profits backed by cash
reduced long-term debt
gross margin widened
assets working harder

Repair signals

Gross margin 98.9% → 100.0%

Trade setup

ATR% 5.6% $0.63 a day · 2×ATR $10.04

RS 91 / 99 vs the universe

Trend 8 / 8 trend template

Relative volume 0.6× vs 50-day average

Up/down volume 0.93 50 sessions

Implied move — no option chain · report Nov 4, 2026

Trend template · 8 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

2 flagged

Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Revenue shrinking Revenue fell 7.6% over the year, from $74.2M to $68.6M.

Last reported Aug 5, 2026

Results reaction Aug 5, 2026-4% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $68.6M -8% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$438.0M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$396.6M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 100%
Net -639%
Free cash -579%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 139.47m +9.5% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$76.4M	$1.1B	$1.6B	$86.2M	$74.2M	$68.6M
Gross margin	100%	94%	91%	97%	99%	100%
Operating income	-$297.0M	$420.8M	$833.1M	-$684.3M	-$587.2M	-$479.3M
Net income	-$298.7M	$528.6M	$515.8M	-$615.1M	-$522.0M	-$438.0M
Net margin	-391%	48%	32%	-714%	-703%	-639%
Earnings per share	-$2.51	$3.96	$3.83	-$4.59	-$3.83	-$3.16
Free cash flow	-$197.5M	-$69.4M	$1.6B	-$800.4M	-$453.7M	-$396.6M
Free cash margin	-259%	-6%	99%	-929%	-611%	-579%
Cash	$436.6M	$347.8M	$848.6M	$241.6M	$222.9M	$232.2M
Shareholders' equity	$716.9M	$1.4B	$2.1B	$1.6B	$1.2B	$765.3M
Shares outstanding	127.42m	131.16m	133.24m	134.78m	136.96m	139.47m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 5, 2026	Quarterly ↗	Jun 30, 2026	36d
May 7, 2026	Quarterly ↗	Mar 31, 2026	37d
Feb 23, 2026	Annual ↗	Dec 31, 2025	54d
Nov 5, 2025	Quarterly ↗	Sep 30, 2025	36d
Aug 6, 2025	Quarterly ↗	Jun 30, 2025	37d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Feb 27, 2025	Annual ↗	Dec 31, 2024	58d
Nov 4, 2024	Quarterly ↗	Sep 30, 2024	35d
Aug 1, 2024	Quarterly ↗	Jun 30, 2024	32d
May 3, 2024	Quarterly ↗	Mar 31, 2024	33d
Feb 26, 2024	Annual ↗	Dec 31, 2023	57d
Nov 3, 2023	Quarterly ↗	Sep 30, 2023	34d

Current reports

Filed	Disclosed
Oct 28, 2026	Director or officer change ↗
Oct 14, 2026	Unregistered share sale · Other events ↗
Oct 8, 2026	Other events ↗
Oct 1, 2026	Director or officer change · Regulation FD ↗
Aug 5, 2026	Results ↗
Jul 24, 2026	Director or officer change ↗
Jun 10, 2026	Director or officer change ↗
May 28, 2026	Director or officer change · Shareholder vote ↗
May 6, 2026	Results ↗
Apr 10, 2026	Director or officer change ↗
Mar 4, 2026	Director or officer change ↗
Mar 2, 2026	Other events ↗